Professor Julia Brown

by | 19 Jul 2022 | Leeds, Supervisors | 0 comments

Professor Julia Brown.Email:

Research profile and key clinical specialties

Julia Brown is Professor of Clinical Trials Research and Director of the Leeds Institute of Clinical Trials Research, which incorporates the Clinical Trials Research Unit.

The CTRU is NCRI-accredited, CRUK Clinical Trials Unit and a UKCRC Registered CTU with a national and international reputation for conducting well designed and executed complex multi-centre clinical trials.

A graduate in medical statistics, Professor Brown spent a number of years in the NHS and Industry before joining the CTRU in 1991.

Her main research interests are in the design and analysis of complex trials and the development and incorporation and analysis of patient reported outcomes in clinical trials. She is a NIHR Senior Investigator.

Two key publications

  • Cook G, Williams C, Brown J, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O’Connor S, Drayson MT, Morris TCM. (2014). High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): A randomised, open-label, phase 3 trial. The Lancet Oncology, 15(8), 874-885.
  • Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T. (2013). Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: Quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The Lancet Oncology, 14(3), 236-243. doi: 10.1016/S1470-2045(12)70567-3 (ICON7) phase 3 randomised trial. The Lancet Oncology, 14(3), 236-243.

Possible PhD projects

  • Biomarker Guided Adaptive Trial Designs

More information

Julia has been Chair of the NIHR HTA general Funding Committee since 2020.


Keywords: Leeds Institute of Clinical Trials Research, ovarian cancer, Ovarian Neoplasms myeloma, chemotherapy, autologous, stem-cell, patient outcome, clinical trials, Julia, Brown, Leeds